The Impact of Platelet-Rich Plasma (PRP) on the Maturation Rates of Arteriovenous Fistulas in End-Stage Renal Disease Patients

Evaluation of the role of Platelet rich plasma in overall success rates of AV fistula in patients with End stage renal disease A randomized study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/078593

Enrollment

Registered

2024-12-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Intervention1: Platelet rich plasma group: Local application Platelet rich plasma in wound bed after AV fistula creation. . AV fistula creation takes around 45 mins. PRP will be applied to wound bed

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria include age over 18 years with ESRD requiring hemodialysis.

Exclusion criteria

Exclusion criteria: Critical thrombocytopenia (low platelet count) Hypofibrinogenaemia Haemodynamic instability (collapse) Acute and chronic infections Chronic liver disease Anti-coagulation therapy (warfarin, dabigatran, heparin) Platelet dysfunction syndrome Local infection at the site of the procedure Hemodialysis port on the Same side

Design outcomes

Primary

Measure	Time frame
Two co-primary end points 1. AVF diameter 2. AVF blood flowTimepoint: Measured at 4th , 6th and 12 th week after AVF creation	—

Secondary

Measure	Time frame
Time to successful cannulation Time to initiation of Hemodialysis. Stenosis rate (at anastomotic site or distal to it). Complication rates (Bleeding, thrombosis, infection, Aneurysm formation, presence of steal phenomenon). Timepoint: Measured at 4th , 6th and 12 th week after AVF creation	—

Countries

India

Contacts

Public ContactDr Manoj Kumar Das

AIIMS Bhubaneswar

urol_manoj@aiimsbhubaneswar.edu.in7894453494

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026